All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Treatment sequencing for anemic myelofibrosis
with Jean-Jacques Kiladjian & Angela Fleischman
Monday, February 26, 2024 | 16:30 CET
This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
Bookmark this article
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Pemmaraju, MD Anderson Cancer Center, Houston, US. We asked, what are some of the promising new drugs in MPN therapy?
Pemmaraju begins by outlining current therapies that are being successfully combined with Janus kinase inhibitors (JAKi) in the frontline treatment setting. These include navitoclax, pelabresib, and selinexor; each combined with the JAKi backbone therapy, ruxolitinib. He then discusses agents aimed at patients who experience suboptimal responses to initial JAKi therapy. Pemmaraju concludes by highlighting novel therapeutic approaches that move beyond the conventional JAKi approach. These include monoclonal antibodies, calreticulin mutant-specific targeting, and the discovery and targeting of novel signaling pathways.
What are some of the promising new drugs in MPN therapy?
Current combination therapies in MPN
Here, we summarize a presentation by John Mascarenhas on the status of combination therapies in MPN from the 15th International Congress on MPN.
Novel MPN therapies: single agents beyond Janus kinase inhibitors
Here, we summarize a presentation by Pemmaraju discussing novel therapies for MPN beyond JAKis, from the 15th International Congress on MPN.
Subscribe to get the best content related to MPN delivered to your inbox